PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩690 per share · Prices as of the 2026-10-02 close
Vieworks has seen its industrial imaging (machine vision) segment lead growth on the back of a semiconductor inspection equipment recovery, with operating margin improving for five consecutive quarters.
The machine vision (industrial imaging) segment grew 24.6% year-on-year in H1 2026, leading overall earnings improvement.
Quarterly operating margin rose steadily from 8.0% in Q3 2025 to 16.7% in Q2 2026.
Q2 2026 net income attributable to owners (KRW 16.64 billion) significantly exceeded operating profit (KRW 10.70 billion), suggesting a possible non-operating contribution.
New businesses such as digital pathology and golf imaging are expanding overseas supply contracts in an effort to diversify revenue sources.
The medical solutions segment, the largest by revenue, remained roughly flat year-on-year in H1 2026.
Vieworks is an imaging solutions specialist built on two pillars: medical imaging solutions and industrial machine vision cameras.
The medical segment consists of static X-ray detectors, video X-ray detectors, industrial X-ray detectors, and other products including bio-imaging and mammography, with static detectors generating the largest revenue of KRW 21.6 billion in Q1 2026.
The company supplies detectors to dental and general radiography equipment customers across Europe, North America, and Asia, and video detector sales to European dental equipment customers recovered in H1 2026.
The industrial imaging (machine vision) segment supplies cameras to semiconductor, display, and PCB inspection equipment customers based on ultra-high-resolution line scan and area scan cameras and hybrid TDI sensor technology.
Machine vision revenue reached KRW 30.2 billion in H1 2026, up 24.6% year-on-year, benefiting from expanded semiconductor inspection equipment investment.
The company is pursuing revenue diversification through new businesses such as digital pathology (the VISQUE DPS slide scanner) and golf imaging (launch monitors), and has signed supply contracts with pathology customers in the United States and Europe.
In golf imaging, alongside its existing ODM business, the company began supplying launch monitors to a US golf imaging brand. Vieworks is classified under the KOSDAQ medical and precision equipment sector, and both its machine vision and medical detector businesses compete with global rivals on technology and price.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩62.7B | ₩6.5B | 10.4% |
| 2025Q3 | ₩53.7B | ₩4.3B | 8.0% |
| 2025Q4 | ₩68.6B | ₩8.5B | 12.4% |
| 2026Q1 | ₩58.2B | ₩8.8B | 15.2% |
| 2026Q2 | ₩63.9B | ₩10.7B | 16.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩237.9B | ₩43.7B | ₩26.5B | 18.3% | 12.7% | 37.8% |
| 2023 | ₩220.3B | ₩18.7B | ₩14.7B | 8.5% | 6.8% | 35.7% |
| 2024 | ₩222.9B | ₩22.3B | ₩21.3B | 10.0% | 9.0% | 36.4% |
| 2025 | ₩239.3B | ₩21.4B | ₩20.9B | 8.9% | 8.4% | 41.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Vieworks' annual revenue declined from KRW 237.9 billion in 2022 to KRW 220.3 billion in 2023, before recovering to KRW 222.9 billion in 2024 and KRW 239.3 billion in 2025, showing gradual growth.
Operating profit fell sharply from KRW 43.66 billion (18.3% margin) in 2022 to KRW 18.74 billion (8.5%) in 2023, then moved between recovery and stagnation at KRW 22.33 billion (10.0%) in 2024 and KRW 21.42 billion (8.9%) in 2025.
Net income attributable to owners fell from KRW 26.54 billion in 2022 to KRW 14.71 billion in 2023, then held steady at roughly KRW 21.30 billion in 2024 and KRW 20.91 billion in 2025.
On a quarterly basis, operating margin was low at 10.4% in Q2 2025 and 8.0% in Q3 2025, then improved steadily to 12.4% in Q4 2025, 15.2% in Q1 2026, and 16.7% in Q2 2026.
This is interpreted as a combination of machine vision segment growth driven by recovering semiconductor inspection equipment demand, a larger mix of higher-value-added products, and improved cost structure including selling and administrative expenses.
The net income trend is even more pronounced: net income attributable to owners rose to KRW 10.47 billion in Q4 2025 and KRW 9.32 billion in Q1 2026, before jumping to KRW 16.64 billion in Q2 2026, exceeding operating profit of KRW 10.70 billion.
This pattern of net income exceeding operating profit suggests non-operating items may have made an additional contribution to recent results, and whether this persists needs to be confirmed in coming quarters.
Net income attributable to owners summed over the most recent four quarters (Q3 2025 through Q2 2026) reached KRW 42.78 billion, surpassing the highest of the last four confirmed annual figures, KRW 26.54 billion in 2022.
The machine vision (industrial camera) market is tied to inspection automation demand in precision manufacturing processes such as semiconductors, displays, and PCBs, and expanded investment in AI semiconductors and advanced packaging such as HBM has recently emerged as a new growth driver.
Vieworks supplies cameras for semiconductor front-end and back-end inspection—including wafer surface defect detection, HBM chip alignment inspection, and TGV inspection in TSV processes—based on hybrid TDI line scan cameras and ultra-high-resolution sensor technology.
At a March 2026 trade show, the company unveiled a 100Gbps-class fiber-optic-based (CoaXPress-over-Fiber) interface solution, signaling an attempt to expand applications into 3D vision, robot vision, and wafer inspection.
The medical imaging equipment market shows gradual growth driven by replacement demand for dental and general radiography equipment and digital transformation, with a high proportion of customers in Europe and North America.
The company is diversifying machine vision applications into battery electrode/cell surface inspection and solar panel surface inspection to reduce dependence on any single industry cycle.
New businesses such as digital pathology and golf imaging remain at an early stage, with limited revenue contribution relative to the existing medical and industrial imaging businesses, but are being cultivated as long-term growth drivers.
The company expects machine vision segment growth driven by the semiconductor inspection equipment recovery to continue in H2 2026, and said it plans to continue developing fiber-optic-based high-speed interface (CoaXPress-over-Fiber) products.
In the medical segment, the company expects recovering demand from large European customers to further contribute to earnings improvement in H2.
The digital pathology business is expanding its distribution through domestic pathology society and major hospital exhibitions, building on supply contracts with US and European customers, and is also considering entry into Asian markets going forward.
In golf imaging, alongside existing ODM supply, the company has begun full-scale launch monitor supply to a US brand, and whether this becomes an established new revenue source is a point to watch.
The company has stated it will "continue the recovery in the industrial segment and entry into new markets for the golf business" in H2. However, these plans are all based on company statements, and the actual timing and scale of revenue recognition need to be confirmed through upcoming quarterly disclosures.
Given the pace of earnings recovery over the most recent four quarters, the multiple placed on the company's market capitalization relative to recent results appears lower than levels implied by past annual confirmed results.
The share price tends to trade near or slightly below net asset value per share, without a large premium to net assets. The dividend yield is not large from a growth-stock perspective, and the company appears to have maintained a policy weighted toward business reinvestment rather than per-share value enhancement.
The historically wide swings—from the high operating margin of 2022 to the subsequent earnings slump and the recent recovery—appear to have also influenced the valuation multiple the market assigns to this stock.
Whether the semiconductor inspection equipment cycle and new business performance continue going forward remains the key variable for valuation judgments.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
Industrial imaging (machine vision) segment revenue grew 24.6% in H1 2026 on the back of expanded global semiconductor inspection equipment investment, driving overall earnings improvement. Sales of customer-specific models centered on TDI line scan cameras for HBM and advanced packaging inspection have expanded. If AI semiconductor investment continues to expand, this trend could persist beyond H2.
Quarterly operating margin has improved for five consecutive quarters, from 8.0% in Q3 2025 to 16.7% in Q2 2026. The company cited a larger mix of higher-value-added products and improved cost structure, including selling and administrative expenses, as the reasons. If this improvement continues, the profitability structure could move to a higher level.
The digital pathology slide scanner has secured supply contracts with US and European customers, and the golf imaging business has begun supplying launch monitors to a US brand, securing new revenue sources.
These are expected to reduce dependence on the cyclicality of existing medical and industrial imaging businesses. However, revenue contribution from both new businesses remains at an early stage.
The medical solutions segment, the largest by revenue, remained roughly flat year-on-year at about KRW 91.8 billion in H1 2026. The company's expectation that recovering demand from large European customers will be reflected in H2 has not yet been confirmed in results. If segment growth is delayed, the overall revenue growth pace could remain limited.
In Q4 2025 and both Q1-Q2 2026, net income attributable to owners exceeded operating profit. This suggests non-operating items may have contributed to recent net income improvement, and if these factors fade, the pace of net income improvement could slow.
Assessing the quality of earnings requires ongoing monitoring of non-operating line items in future quarterly income statements.
As seen when operating margin plunged from 18.3% in 2022 to 8.5% in 2023, the company's results have historically swung sharply with downstream capex cycles in semiconductors and displays. How long the recent recovery lasts depends on downstream investment cycles.
With a relatively small revenue base, volatility tied to dependence on specific customers and products also persists.
Machine vision segment results are heavily influenced by the capex cycles of semiconductor and display equipment makers. If downstream investment contracts as it did in 2022-2023, operating margin could decline sharply again.
The company is trying to reduce this dependence by expanding applications into batteries and solar, but this remains at an early stage.
Digital pathology and golf imaging are early-stage businesses with limited revenue contribution so far, and each must succeed in markets with different entry barriers such as regulatory approval or brand competition. If overseas distribution does not expand as planned, returns on new business investment could be delayed.
With an export-oriented structure heavily weighted toward European and North American customers, KRW exchange rate movements directly affect revenue and earnings.
FX-related gains may have influenced recent quarters where net income exceeded operating profit, meaning a shift in currency direction could work in the opposite direction.
The expected timing of the Q3 preliminary earnings disclosure, when it can be confirmed whether the machine vision segment's semiconductor inspection equipment demand recovery and operating margin improvement trend continue.
The Q3 quarterly report filing, which should reveal detailed segment revenue for medical, industrial, and other businesses as well as the composition of non-operating items.
Whether and to what extent the golf imaging new business (launch monitor supply to a US brand) begins contributing to reported revenue.
Based on the historical pattern of annual preliminary results and dividend decisions being disclosed together around mid-February each year, this is when 2026 full-year confirmed results and dividend policy can be checked.
Whether new supply contracts related to the digital pathology business's entry into Asian markets are signed.
Vieworks has entered an earnings recovery phase, underpinned by strong growth in the machine vision segment driven by recovering semiconductor inspection equipment demand and operating margin improvement for five consecutive quarters.
However, the medical solutions segment, the largest by revenue, has yet to show clear growth, and the recent pattern of net income exceeding operating profit warrants monitoring for the sustainability of non-operating factors.
New businesses such as digital pathology and golf imaging are being cultivated as long-term growth drivers through expanded overseas supply contracts, but their revenue contribution remains at an early stage.
The sharp earnings swings of 2022-2023 illustrate that the company's results remain sensitive to downstream capex cycles.
Going forward, the Q3 preliminary results, the recovery of demand from large medical-segment customers, and the timing of revenue contribution from new businesses will be key variables in gauging the sustainability of the current earnings trend.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.